In 2021, the Global Inhaled Nitric Oxide Delivery Systems market was estimated to be worth around USD 273.7 million.
With the increasing expenditure incurred on treating respiratory diseases with Inhaled Nitric Oxide Delivery Systems worldwide, the market is expected to reach a worth of about USD 735.7 million by the end of 2032, with a projected CAGR of 9.5% from 2022 to 2032. From 2017 to 2021, the Inhaled Nitric Oxide Delivery Systems Market experienced a growth of 8.5%.
| Attributes | Details |
|---|---|
| Global Inhaled Nitric Oxide Delivery Systems Market Size (2021) | USD 273.7 million |
| Global Inhaled Nitric Oxide Delivery Systems Market Size (2022) | USD 297.3 million |
| Projected Market Value (2032) | USD 735.7 million |
| Global Market Growth Rate (2022 to 2032) | 9.5% CAGR |
| United States Inhaled Nitric Oxide Delivery Systems Market (2022) | USD 104.7 million |
| Key Companies Profiled | Mallinckrodt Pharmaceuticals; Getinge; Vero Biotech; LINDE; Beyond Air; SLE; NU MED; Bellerophon Therapeutics; Air Liquide Healthcare; Circassia Pharmaceuticals |
More than 50% of patients with respiratory diseases need hospital admission. Increased Research and Development efforts that result in novel applications for inhaled nitric oxide delivery systems in the healthcare sector are the key factor fuelling the growth of the global inhaled nitric oxide delivery systems market. In addition, an aging population with weakened lung function drives the demand for inhaled nitric oxide delivery systems globally.
Nitric oxide inhalation (INO), a minimally invasive therapy, is becoming more popular, which is causing the market to grow. Research conducted in 2020 revealed that inhaled nitric oxide is effective in treating SARS-CoV-2 infection. Like traditional medications, it is also a successful therapy for COVID-19 patients. As a result, during the pandemic, there was a sharp increase in demand for inhaled nitric oxide delivery systems.
Additionally, ARDS (acute respiratory distress syndrome), a symptom in COVID-19 patients, is well treated with inhaled nitric oxide delivery systems. INO helps COVID-19 patients by increasing oxygen circulation. These factors are therefore expected to improve the opportunities for market growth for inhaled nitric oxide delivery systems. Important market participants like Mallinckrodt Pharmaceuticals are sponsoring more clinical trials of inhaled nitric oxide therapy.
During the following ten years, these activities will also drive the market's expansion. The year 2020 saw an overwhelming demand for Inhaled Nitric oxide delivery systems due to increasing cases of Covid-19.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
North America holds the largest market for Inhaled Nitric Oxide Delivery Systems and is likely to grow at a rapid pace in the next 10 years. This growth is because of the increasing cases of HRF in the region. In addition to this, the rising adoption of INO therapy, the presence of advanced medical infrastructure, and favorable government initiatives are expected to bolster growth avenues in the market.
Asthma affects more than 25 million people in the USA. 12 million adults have not yet received a COPD diagnosis, despite there being 14.8 million adults with the condition. In the USA, phase two and phase three clinical trials of inhaled nitric oxide for acute respiratory distress syndrome use the inhaled nitric oxide delivery method on a regular basis.
In 2020, more than 300,000 deaths from respiratory disorders were recorded in Canada. Five significant respiratory disorders, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, tuberculosis (TB), and cystic fibrosis, afflict the majority of Canadians. As these illnesses become more prevalent, the need for inhaled nitric oxide delivery systems in the area is growing along with them.
Asia Pacific has the fasted growing market for Inhaled Nitric Oxide Delivery Systems. This is mainly due to the increasing pollution and growing pediatric population in the region.
In Asia Pacific, China accounts for the largest share of the market for Inhaled Nitric Oxide Delivery Systems followed by India. This is because COPD is rapidly becoming recognized as a severe health issue in China. According to estimations, 8.2% of Chinese people have COPD, and the disease's death rate is around 1.6%.
In India, respiratory infections caused 41,996,260 illnesses and 3,740 deaths in 2018, according to the National Health Portal of India. Severe acute respiratory infections (SARI) are one of the leading causes of death in children under the age of five, accounting for 18% of the global population in India. As a result, there is a sharp rise in the demand for inhaled nitric oxide delivery systems in the country.
The USA holds the largest market for Inhaled Nitric Oxide Delivery Systems, which is projected to reach a valuation of USD 258.4 million by 2032. From 2017 to 2021, the market in the US grew at a CAGR of 8.8%. Between 2022 and 2032, the US is expected to be a market with a USD 153.7 million absolute dollar opportunity.
Since there are between 64.2 and 78.9 cases of ARDS per 100,000 people per year in the US, there exists a significant demand for Inhaled Nitric Oxide Delivery systems. Around 25% of ARDS patients are initially categorized as mild, with the remaining 75% being categorized as moderate or severe. A sickness that is moderate or severe develops in one-third of mild cases.
A further estimate places the annual number of term and late-preterm newborns in the USA with HRF at 80,000. In neonatal intensive care units (NICUs), respiratory morbidity affects about 15% of term newborns and 29% of late-preterm infants. These are the key reasons for the increasing demand for Inhaled Nitric Oxide Delivery Systems in the country.
In 2021, the market size of China is comparatively small. It was the second-largest Inhaled Nitric Oxide Delivery Systems Market after the US. The market in the country is expected to reach a valuation of USD 88.4 million by 2032. From 2017 to 2021, the market in China experienced a CAGR of 9.9% and is expected to experience a CAGR of 10.7% with an absolute dollar opportunity of USD 56.4 million.
With the increasing number of smokers in the country, respiratory diseases are also becoming quite common. In China, almost 1 million people know of COPD, which presents a significant opportunity for INO delivery systems marketers, as inhalation of nitric oxide has been clinically proven to improve the oxygenation of arterial blood flow and limit the amount of mechanical-assisted breathing treatments in patients with the severe acute respiratory syndrome (SARS).
The inhaled nitric oxide delivery systems market in the UK was held at USD 12.3 million in 2021. The market is projected to reach a valuation of USD 37.4 million by 2032. The UK market is expected to witness an absolute dollar opportunity of USD 24 million.
The inhaled nitric oxide delivery systems market in Japan is estimated at USD 9.1 million in 2022. The market in the country is projected to reach a valuation of USD 21.2 million by 2032. From 2022 to 2032, the market is expected to gross an absolute dollar opportunity of USD 12.1 million, growing at a CAGR of 8.8%.
Principal Consultant
Inhaled Nitric Oxide Delivery Systems are used the most among pediatrics. From 2017 to 2021, the use of INO Delivery Systems among pediatrics experienced a CAGR of 8.9% and is expected to witness a CAGR of 9.8% in the next ten years.
Inhaled nitric oxide has been significantly effective in the treatment of neonatal diseases such as hypoxic respiratory failure (HRF). In the USA alone, over 25,000 to 30,000 newborn HRF cases are recorded each year, wherein Inhaled Nitric Oxide Delivery System is used for treatment to cure more than half of them.
Inhaled Nitric Oxide Delivery Systems are used the most in the treatment of Hypoxic Respiratory Failure. The use of the INO delivery system in the treatment of HRF from the year 2017 to 2021 experienced a CAGR of 8.8% and is projected to experience a CAGR of 9.6% from 2022 to 2032.
In 2020, the treatment of Hypoxic Respiratory Failure using Inhaled Nitric Oxide Delivery Systems made up 80.2% of the overall market. Around 2% of all live births and those affected by HRF is also responsible for more than 33% of all neonatal deaths. The death of 18 out of every 1,000 newborns, the majority of whom are born prematurely in the USA, is due to the HRF. According to studies, Inhaled Nitric Oxide is used as the first line of treatment for HRF and it can be used for more than 10 days without causing complications.
The Inhaled Nitric Oxide Delivery Systems market is moderately competitive and has numerous players. With the growing demand for Inhaled Nitric Oxide Systems, new players are also entering the market. The key companies operating in the Inhaled Nitric Oxide Delivery Systems Market are Mallinckrodt Pharmaceuticals, Getinge, VERO Biotech, LINDE, Beyond Air, SLE, NU MED, Bellerophon Therapeutics, Air Liquide Healthcare, and Circassia Pharmaceuticals.
Some of the recent developments by the key providers of Inhaled Nitric Oxide Delivery Systems are as follows:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global Inhaled Nitric Oxide Delivery Systems Market was valued at USD 273.7 million in 2021 and is expected to account for an absolute dollar opportunity of USD 438.4 million by 2032.
Over the projected period, the Inhaled Nitric Oxide Delivery Systems Market is expected to increase at a CAGR of 9.5%, reaching a value of USD 735.7 million by 2032.
The growing number of respiratory diseases among all age groups especially during the pandemic is driving the market for Inhaled Oxide Delivery Systems.
The Inhaled Nitric Oxide Delivery Systems Market expanded at a CAGR of 8.5% from 2017 through 2021.
Mallinckrodt Pharmaceuticals, Getinge, Vero Biotech, LINDE, Beyond Air, SLE, NU MED, Bellerophon Therapeutics, Air Liquide Healthcare, and Circassia Pharmaceuticals, are some of the key players in the Inhaled Nitric Oxide Delivery Systems Industry.
The USA, UK, China, Japan, and South Korea are expected to drive the most Inhaled Nitric Oxide Delivery Systems.
The US accounts for the largest market for Inhaled Nitric Oxide Delivery Systems.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Type 5.1. Pediatrics 5.2. Adult 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application 6.1. Hypoxic Respiratory Failure (HRF) 6.2. Acute Hypoxemic Respiratory Failure (AHRF) 6.3. Other Applications 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User 7.1. Hospitals 7.2. Ambulatory Centres 7.3. Clinics 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Type 8.1. Disposables 8.2. System 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. Asia Pacific 9.5. Middle East and Africa (MEA) 10. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Mallinckrodt Pharmaceuticals 17.2. Getinge 17.3. Vero Biotech 17.4. LINDE 17.5. Beyond Air 17.6. SLE 17.7. NU MED 17.8. Bellerophon Therapeutics 17.9. Air Liquide Healthcare 17.10. Circassia Pharmaceuticals 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Inhaled Nitric Oxide Delivery Systems Market
